Fig. 1: Schematic structure of CS1-BCMA CAR and time to recovery of grade 3-4 cytopenias.
From: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
A Schematic structure of CS1-BCMA CAR containing MNDU3 promoter, CD8 signal peptide (SP), anti-CS1 single-chain fragment variable (scFv) linked with a novel anti-BCMA scFv, CD8 hinge and transmembrane domain, 4-1BB costimulatory domain and CD3ζ signaling domain. B Time to recovery of grade 3–4 cytopenias. Patients with grade 3–4 cytopenias (leukopenia (n = 16), neutropenia (n = 15), lymphopenia (n = 16), anemia (n = 2) and thrombocytopenia (n = 5)) after infusion are included. Recovery is defined as cytopenias of grade 2 or better (absolute leukocyte counts ≥2000 cells/μL, absolute neutrophil counts ≥1000 cells/μL, absolute lymphocyte counts ≥500 cells/μL, hemoglobin concentration ≥80 g/L, or platelets ≥50,000/μL). Time to recovery is defined as the time from infusion to the first time when recovery criteria was met.
